SpringWorks Therapeutics Net Income 2011-2026 | SWTX

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income SpringWorks Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-258 M	-325 M	-277 M	-174 M	-45.6 M	-58.3 M	-17.8 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-17.8 M	-325 M	-165 M

Quarterly Net Income SpringWorks Therapeutics

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-83.2 M	-	-53.5 M	-39.9 M	-87.4 M	-	-79.4 M	-77.9 M	-73.4 M	-	-72.4 M	-69 M	-61.8 M	-	-41 M	-47 M	-29.8 M	-	-21.7 M	-19.9 M	-15.3 M	-16.2 M	-16.8 M	-13.8 M	-11.4 M	-6.22 M	-5 M	-4.02 M	-2.57 M	-4.64 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-2.57 M	-87.4 M	-38.1 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
Amgen AMGN	7.71 B	$ 350.13	2.98 %	$ 188 B	USA
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	-253 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	-131 M	-	-	$ 86.2 M	USA
Amneal Pharmaceuticals AMRX	72.1 M	$ 12.73	3.33 %	$ 3.99 B	USA
AlloVir ALVR	-43.4 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-126 M	-	-	$ 10.1 M	USA
argenx SE ARGX	-408 M	$ 783.17	2.32 %	$ 25 B	Niderland
Autolus Therapeutics plc AUTL	-288 M	$ 1.48	8.82 %	$ 394 M	Britain
Applied Therapeutics APLT	-120 M	-	-	$ 8.42 M	USA
I-Mab IMAB	-1.47 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	67.3 M	-	2.54 %	$ 160 B	France
Arcutis Biotherapeutics ARQT	-16.1 M	$ 24.57	5.59 %	$ 3.13 B	USA
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
AVROBIO AVRO	12.2 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	-38 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	115 M	-	-	$ 96.9 B	Britain
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
BioNTech SE BNTX	10.3 B	$ 91.64	2.25 %	$ 27.2 B	Germany
BeiGene, Ltd. BGNE	287 M	-	0.49 %	$ 251 B	Cayman-islands
Alterity Therapeutics Limited ATHE	-12.8 M	$ 3.82	1.6 %	$ 9.19 B	Australia
Burford Capital Limited BUR	172 M	$ 4.62	1.54 %	$ 742 M	Britain
CymaBay Therapeutics CBAY	-105 M	-	-	$ 3.45 B	USA
Advaxis ADXS	-48.1 M	-	-9.65 %	$ 45.9 M	USA
Aytu BioScience AYTU	-13.6 M	$ 2.68	4.28 %	$ 16.8 M	USA
Avid Bioservices CDMO	-141 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	-170 M	-	-	$ 1.41 B	USA
Can-Fite BioPharma Ltd. CANF	-7.88 M	$ 3.05	0.66 %	$ 6.64 B	Israel
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
Cabaletta Bio CABA	-168 M	$ 3.05	-0.5 %	$ 306 M	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Aeterna Zentaris AEZS	-8.37 M	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Cerus Corporation CERS	-15.6 M	$ 1.93	4.62 %	$ 368 M	USA
AgeX Therapeutics AGE	-19.2 M	-	-10.17 %	$ 12.2 K	USA
Concert Pharmaceuticals CNCE	-80.1 M	-	-	$ 401 M	USA
Aeglea BioTherapeutics AGLE	-155 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-18.4 M	-	-	$ 26.5 M	USA
CTI BioPharma Corp. CTIC	-93 M	-	-	$ 1.2 B	USA
AIkido Pharma AIKI	-22.4 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	-25.5 M	-	-45.71 %	$ 1.2 M	Canada
Cyclacel Pharmaceuticals CYCCP	-3 M	-	-4.36 %	$ 27 M	USA
Cellectar Biosciences CLRB	-21.8 M	$ 2.83	2.91 %	$ 7.38 M	USA
Deciphera Pharmaceuticals DCPH	-195 M	-	-	$ 2.18 B	USA
Akero Therapeutics AKRO	-252 M	-	-	$ 3.67 B	USA
Dynavax Technologies Corporation DVAX	27.3 M	-	-	$ 2.02 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Coherus BioSciences CHRS	168 M	$ 1.73	3.59 %	$ 203 M	USA